An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy

NCT02090959 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

219

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision due to commercial availability of ataluren.

Conditions

Muscular Dystrophy, Duchenne
Muscular Dystrophies
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, X-Linked
Genetic Diseases, Inborn

Interventions

DRUG: Ataluren

Sponsor

PTC Therapeutics